文献速递肿瘤 PET/CT

68Ga-PSMA PET/CT 在原发性及疑似复发肾细胞癌分期中的应用

The use of 68Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-07-23

38例扫描中,初诊分期16例管理改变43.8%,再分期22例改变40.9%,总体改变42.1%,透明细胞亚型检出率最高。

要点

  • 68Ga-PSMA PET/CT总体使42.1%的肾细胞癌患者管理发生改变。
  • 初诊分期管理改变43.8%,再分期管理改变40.9%。
  • 管理改变主要源于发现新疑似转移灶及同步原发灶。

核心结论

  • 68Ga-PSMA PET/CT直接改变了42.1%肾细胞癌病例的管理。
  • 透明细胞肾细胞癌患者的检出率最高。
  • 结果提示该模态在肾细胞癌分期中可能具有价值,但需进一步验证组织学确认、疗效与成本效益。

研究设计与样本

  • 共38次68Ga-PSMA PET/CT扫描符合纳入标准,其中初诊分期16例、再分期22例。
  • 主要结局指标为对比标准诊断CT成像,评估68Ga-PSMA PET/CT是否改变管理。
  • 分析基于四类:发现新病灶、否定CT所见病灶、发现同步原发灶、与CT的一致性。

主要发现

  • 初诊分期16例中,75%显示原发性病灶摄取,多数为透明细胞亚型。
  • 初诊分期患者中43.8%管理改变,CT与68Ga-PSMA PET/CT一致率为37.5%。
  • 再分期22例中40.9%管理改变,CT与68Ga-PSMA PET/CT一致率为36.4%。
  • 管理改变主要由于发现新疑似转移灶及检出同步原发灶。

关键数值与推荐

  • 初诊分期:75%原发灶摄取,43.8%管理改变,CT一致率37.5%。
  • 再分期:40.9%管理改变,CT一致率36.4%。
  • 总体:42.1%病例管理改变。

临床怎么用

  • 在肾细胞癌分期或再分期中,68Ga-PSMA PET/CT可提供改变管理决策的信息,尤其对透明细胞亚型检出率较高。
  • 管理改变多源于发现新疑似转移灶或同步原发灶,提示该模态可能影响治疗策略。
  • 目前证据尚不足以支持常规使用,需结合组织学确认、疗效与成本效益进一步评估。

局限性

  • 回顾性病例系列设计,样本量有限(38次扫描)。
  • 需进一步分析组织学确认、疗效及成本效益以确定常规应用价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The role of 68Ga-PSMA PET/CT in the staging of prostate cancer is well known. PSMA is also overexpressed in the neovasculature of other tumours including renal cell carcinoma (RCC), suggesting there may be a role for the use of 68Ga-PSMA PET/CT. Thus far, there has been limited literature documenting the use of 68Ga-PSMA PET/CT in the investigation and management decisions of RCC. METHODS: This was a retrospective case series of patients who received a 68Ga-PSMA PET/CT scan for staging or restaging of RCC between July 2016 and December 2018. Primary outcome measure was to identify whether 68Ga-PSMA PET/CT changed management compared to standard diagnostic CT imaging. Analysis was based on four categories: (1) identification of new disease, (2) refuting disease on CT imaging, (3) identification of synchronous primaries, and (4) concordance with CT imaging. RESULTS: 38 68Ga-PSMA PET/CT scans met inclusion criteria. Primary staging scans were performed in 16 patients, of which 75% showed avid primary lesions, with the majority of clear cell subtype. Management was changed in 43.8% of patients. CT agreed with 68Ga-PSMA PET/CT in 37.5% of cases. Restaging scans were performed in 22 patients. 40.9% of patients had management changed by results of 68Ga- PSMA PET/CT. CT agreed with 68Ga- PSMA PET/CT in 36.4% of cases. Management was predominantly changed due to the identification of new sites of suspected metastases, as well as the detection of synchronous primaries. CONCLUSIONS: 68Ga-PSMA PET/CT directly changed management in 42.1% of cases. Strongest detection rates occurred in those patients with clear cell RCC. The results of this study suggest there may be merit in the use of the modality in the staging of RCC. Further analysis, both with respect to histological confirmation, efficacy and cost-benefit, is required to determine whether there is a role for routine 68Ga-PSMA PET/CT imaging.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Raveenthiran S, Esler R, Yaxley J, et al. The use of 68Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2019. PMID: 31332498. doi:10.1007/s00259-019-04432-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。